|
Zenith Keystone Talk, Tues 3/19
|
3
|
Zenith Epigenetics
|
Mar 15, 2019 01:51PM
|
|
Zenith June 30th Special Meeting Information Circular
|
5
|
Resverlogix Corp.
|
Jun 09, 2015 11:34AM
|
|
Zenith is Alive!
|
7
|
Zenith Epigenetics
|
Aug 14, 2017 01:55PM
|
|
Zenith hiring Senior Director of Clinical Operations
|
6
|
Resverlogix Corp.
|
Dec 01, 2015 11:50AM
|
|
Zenith has been quiet.......too quiest
|
2
|
Zenith Epigenetics
|
Jun 03, 2016 02:25PM
|
|
Zenith Files Notice of Annual and Special Meeting of Shareholders
|
1
|
Zenith Epigenetics
|
Nov 21, 2020 08:48AM
|
|
Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
|
5
|
Zenith Epigenetics
|
Jun 21, 2022 08:03AM
|
|
Zenith Epigenetics Receives US$5 Million Milestone Payment from Newsoara
|
3
|
Zenith Epigenetics
|
Jan 07, 2020 09:11AM
|
|
Zenith Epigenetics Corp. Commences Operations
|
3
|
Zenith Epigenetics
|
Dec 07, 2015 11:22AM
|
|
Zenith Epigenetics Corp. Announces Name Change & Corporate Reorganization
|
5
|
Zenith Epigenetics
|
Aug 02, 2016 10:36AM
|
|
Zenith Epigenetics Appoints Dr. Norman C.W. Wong to the Board of Directors
|
2
|
Zenith Epigenetics
|
Dec 07, 2015 11:27AM
|
|
Zenith Epigenetics Appoints Dr. Norman C.W. Wong to the Board of Directors
|
3
|
Resverlogix Corp.
|
Dec 01, 2015 09:56AM
|
|
Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains
|
6
|
Zenith Epigenetics
|
Oct 01, 2018 09:43AM
|
|
Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
|
4
|
Zenith Epigenetics
|
Sep 04, 2018 08:52AM
|
|
Zenith Epigenetics Announces Publication in Journal of Cancer Gene Therapy with Compelling Data for Treatment of ER-Positive Breast Cancer Patients
|
3
|
Zenith Epigenetics
|
Aug 17, 2021 09:42PM
|
|
Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial
|
6
|
Zenith Epigenetics
|
May 10, 2022 12:08PM
|
|
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
|
3
|
Zenith Epigenetics
|
Jun 27, 2019 08:36AM
|
|
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
|
3
|
Zenith Epigenetics
|
Mar 15, 2021 01:16PM
|
|
Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications
|
3
|
Zenith Epigenetics
|
Oct 05, 2020 08:24AM
|
|
Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer
|
5
|
Zenith Epigenetics
|
Nov 20, 2018 09:58AM
|
